Elasomeran/Davesomeran

mRNA-1283 induced a more robust immune response compared to Spikevax® COVID-19 vaccine, mRNA-1273.222 Next-generation mRNA vaccine design offers the potential of longer shelf life and storage advantages, and paves the way for combination vaccine against influenza and COVID-19, mRNA-1083 CAMBRIDGE, MA / ACCESSWIRE / March 26, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that mRNA-1283, the Company's next-generation COVID-19 vaccine, has successfully met the primary endpoints of its Phase 3 clinical trial, demonstrating a higher immune response against SARS-CoV-2 when compared to mRNA-1273.222, Moderna's licensed COVID-19 vaccine. "We are excited to announce our fourth infectious disease vaccine program with positive Phase 3 data, further validating our robust mRNA platform," said Stéphane Bancel, Chief Executive Officer of Moderna. "mRNA-1283 is a critical component of our combination vaccine against flu and COVID-19, mRNA-1083, and this milestone gives us confidence in our ability to bring this much needed vaccine to market." In the NextCOVE (NCT05815498) Phase 3 pivotal trial, mRNA-1283 was shown to elicit a higher immune response against both the Omicron BA.4/BA.5 and original virus strains of SARS-CoV-2, compared to mRNA-1273.222. Importantly, this benefit was most acutely seen in participants over the age of 65 years, the population that remains at highest risk for severe outcomes from COVID-19. The most common solicited local adverse event was injection site pain. The most common solicited systemic adverse events included headache, fatigue, myalgia and chills. The NEXTCove clinical trial is a randomized, observer-blind, active-controlled study of approximately 11,400 individuals aged 12 years and older in the United States, United Kingdom and Canada. mRNA-1283 was found to have a similar safety pro Moderna's approved COVID-19 vaccines. The storage, shelf life and pre-filled syringe presentation of mRNA-1283 could alleviate healthcare provider burden and potentially increase access into new settings to serve public health. A detailed analysis of the Phase 3 clinical trial data for mRNA-1283 will be shared at the Company's Vaccines Day event on March 27 and presented at upcoming scientific conferences. About Moderna Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Spikevax® is a registered trademark of Moderna. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the potential longer refrigerator shelf life and storage advantages of mRNA-1283 compared to Spikevax; and the ability of mRNA-1283 to maintain effectiveness compared to Spikevax. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at . Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release. Moderna Contacts Media: Elise Meyer Sr. Director, Corporate Communications +1 617-852-7041 Elise.Meyer@modernatx.com Investors: Lavina Talukdar Senior Vice President & Head of Investor Relations +1 617-209-5834 Lavina.Talukdar@modernatx.com SOURCE: Moderna, Inc. View the original press release on accesswire.com

Moderna’s boom days are beginning to look like a thing of the past as the biotech is preparing for declining Covid-19 vaccine sales, and heavy investments in R&D on the flu, RSV and potential cancer vaccines. The company reported a predicted drop in income but stuck to its annual sales forecast of $5 billion for its COVID-19 vaccines on Thursday’s Q4 and full year 2023 investors call . That’s less than a third of what the company hauled in for 2022 in Covid vaccine sales, which totaled $18.4 billion. A little less than half of that 2023 figure, or $2 billion, is expected in the first half of this year. Moderna has advance purchase agreements for Covid vaccines with Canada, Kuwait, Switzerland, Taiwan and the UK, as well as 2022 deferral contracts including Japan, the EU and South Korea. There are ongoing talks with the US for 2023 commercial contracts, and the “potential” for more sales to the EU, Japan, Australia, Asia and Latin America. “Given this need we estimate the U.S, fall 2023 Covid market volume to be approximately 100 million doses,” said Arpa Garay, chief commercial officer at Moderna, during today’s Q4 call. “We based this assumption after looking at 2022 vaccination rates and including potential recommendations for two-dose booster series for high risk individuals.” While the total revenue was $19.3 billion for 2022, compared to $18.5 billion in 2021, the increase was mostly because of increased sales of Covid vaccines, according to the company’s press release . Moderna also reported several major quarterly charges including $297 million in inventory write-downs related to expired Covid vaccines, related cancellation charges of $281 million, and an expense for unutilized manufacturing capacity and related contract manufacturing organization charges of $376 million. “These charges, other than royalties, are driven by costs associated with surplus production capacity, overall lower demand and a shift to our most recent Omicron-targeting COVID-19 bivalent booster, mRNA-1273.222,” the company said. Focus is now shifting to its vaccine candidates against RSV, the seasonal flu and cancer as the company branches out to get more products approved, while its vaccine remains the only one on the market. Company leaders reiterated that its RSV vaccine, mRNA-1345, received breakthrough therapy designation from FDA in January, and Moderna is planning on filing for regulatory approval this year. Moderna announced yesterday that its personalized cancer vaccine in combination with Merck’s blockbuster cancer drug Keytruda as adjuvant treatment for patients with high-risk melanoma also received breakthrough therapy designation, and the company is planning on starting a Phase III trial this year with a plan to move into non-small cell lung cancer too. Moderna has a serious competitor in BioNTech , which is developing vaccines in advanced melanoma, ovarian cancer and non-small cell lung cancer, as well as its individualized vaccine, RO7198457. “Ultimately, we’ll go first into other adjuvant indications where we think there’s the most immediate biologic benefit, or biologic rationale for potential benefit that we’ll be looking to demonstrate,” said company president Stephen Hoge. “But obviously, as others start to move into the space, if they show benefits in other lines of therapy, we will absolutely want to proceed very quickly in those directions as well.”